EnteroMedics narrows losses in Q3, aims for 2014 commercialization

Mon, 10/29/2012 - 9:45am
Mass Device

EnteroMedics narrows Q3 losses by 20%, with lower spending on research & development in the 3 months ended September 30.

EnteroMedics logo

EnteroMedics (NSDQ:ETRM) narrowed its losses during its 3rd quarter, cutting its research & development expenses nearly in half.

The weight-loss neurostimulation devices maker posted $5.8 million in net losses, or 14¢ per share, 1¢ above the analysts' expectations. That compared with a net loss of $7.3 million, or 26¢ per share, during the same period last year. No sales were reported for either term.

EnteroMedics, a development-stage company, is working on a device that stimulates the vagus nerve with high frequency, low energy electrical impulses in order to treat obesity.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.